Go Pro
→ Do NOT Buy SpaceX – Do This Instead (From Stansberry Research) (Ad)tc pixel Free ARDS Stock Alerts

Aridis Pharmaceuticals (ARDS) Competitors

Aridis Pharmaceuticals logo
Compare

ARDS vs. VINC, SCPS, SMFL, VRPX, and NAVB

Should you buy Aridis Pharmaceuticals stock or one of its competitors? MarketBeat compares Aridis Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Aridis Pharmaceuticals include Vincerx Pharma (VINC), Scopus BioPharma (SCPS), Smart for Life (SMFL), Virpax Pharmaceuticals (VRPX), and Navidea Biopharmaceuticals (NAVB). These companies are all part of the "pharmaceutical products" industry.

How does Aridis Pharmaceuticals compare to Vincerx Pharma?

Vincerx Pharma (NASDAQ:VINC) and Aridis Pharmaceuticals (NASDAQ:ARDS) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, dividends, profitability, analyst recommendations, media sentiment, earnings and valuation.

Aridis Pharmaceuticals' return on equity of 0.00% beat Vincerx Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Vincerx PharmaN/A -248.33% -132.73%
Aridis Pharmaceuticals N/A N/A N/A

In the previous week, Vincerx Pharma's average media sentiment score of 0.00 equaled Aridis Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Vincerx Pharma Neutral
Aridis Pharmaceuticals Neutral

Vincerx Pharma has a beta of 1.46, meaning that its share price is 46% more volatile than the broader market. Comparatively, Aridis Pharmaceuticals has a beta of 44.97, meaning that its share price is 4,397% more volatile than the broader market.

Vincerx Pharma is trading at a lower price-to-earnings ratio than Aridis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vincerx PharmaN/AN/A-$40.16M-$5.31N/A
Aridis PharmaceuticalsN/AN/A-$30.37M$0.09N/A

44.0% of Vincerx Pharma shares are held by institutional investors. Comparatively, 9.6% of Aridis Pharmaceuticals shares are held by institutional investors. 15.6% of Vincerx Pharma shares are held by company insiders. Comparatively, 5.5% of Aridis Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Aridis Pharmaceuticals beats Vincerx Pharma on 6 of the 8 factors compared between the two stocks.

How does Aridis Pharmaceuticals compare to Scopus BioPharma?

Aridis Pharmaceuticals (NASDAQ:ARDS) and Scopus BioPharma (NASDAQ:SCPS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, valuation, profitability, media sentiment, analyst recommendations, earnings, institutional ownership and dividends.

9.6% of Aridis Pharmaceuticals shares are held by institutional investors. 5.5% of Aridis Pharmaceuticals shares are held by insiders. Comparatively, 5.1% of Scopus BioPharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aridis PharmaceuticalsN/AN/A-$30.37M$0.09N/A
Scopus BioPharmaN/AN/A-$11.61MN/AN/A

Aridis Pharmaceuticals has a beta of 44.97, suggesting that its share price is 4,397% more volatile than the broader market. Comparatively, Scopus BioPharma has a beta of -0.25, suggesting that its share price is 125% less volatile than the broader market.

Company Net Margins Return on Equity Return on Assets
Aridis PharmaceuticalsN/A N/A N/A
Scopus BioPharma N/A N/A N/A

In the previous week, Aridis Pharmaceuticals' average media sentiment score of 0.00 equaled Scopus BioPharma'saverage media sentiment score.

Company Overall Sentiment
Aridis Pharmaceuticals Neutral
Scopus BioPharma Neutral

Summary

Aridis Pharmaceuticals beats Scopus BioPharma on 3 of the 4 factors compared between the two stocks.

How does Aridis Pharmaceuticals compare to Smart for Life?

Aridis Pharmaceuticals (NASDAQ:ARDS) and Smart for Life (NASDAQ:SMFL) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, media sentiment, risk, valuation, earnings and dividends.

Aridis Pharmaceuticals has a beta of 44.97, meaning that its share price is 4,397% more volatile than the broader market. Comparatively, Smart for Life has a beta of 15.06, meaning that its share price is 1,406% more volatile than the broader market.

Company Net Margins Return on Equity Return on Assets
Aridis PharmaceuticalsN/A N/A N/A
Smart for Life N/A N/A N/A

9.6% of Aridis Pharmaceuticals shares are held by institutional investors. Comparatively, 28.4% of Smart for Life shares are held by institutional investors. 5.5% of Aridis Pharmaceuticals shares are held by insiders. Comparatively, 31.7% of Smart for Life shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Aridis Pharmaceuticals' average media sentiment score of 0.00 equaled Smart for Life'saverage media sentiment score.

Company Overall Sentiment
Aridis Pharmaceuticals Neutral
Smart for Life Neutral

Smart for Life has higher revenue and earnings than Aridis Pharmaceuticals. Smart for Life is trading at a lower price-to-earnings ratio than Aridis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aridis PharmaceuticalsN/AN/A-$30.37M$0.09N/A
Smart for Life$11.11M0.00-$22.68M-$14.48N/A

Summary

Smart for Life beats Aridis Pharmaceuticals on 4 of the 7 factors compared between the two stocks.

How does Aridis Pharmaceuticals compare to Virpax Pharmaceuticals?

Aridis Pharmaceuticals (NASDAQ:ARDS) and Virpax Pharmaceuticals (NASDAQ:VRPX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment, valuation and dividends.

Aridis Pharmaceuticals' return on equity of 0.00% beat Virpax Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Aridis PharmaceuticalsN/A N/A N/A
Virpax Pharmaceuticals N/A -1,554.34%-338.29%

In the previous week, Aridis Pharmaceuticals' average media sentiment score of 0.00 equaled Virpax Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Aridis Pharmaceuticals Neutral
Virpax Pharmaceuticals Neutral

Virpax Pharmaceuticals is trading at a lower price-to-earnings ratio than Aridis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aridis PharmaceuticalsN/AN/A-$30.37M$0.09N/A
Virpax PharmaceuticalsN/AN/A-$15.19M-$123.25N/A

9.6% of Aridis Pharmaceuticals shares are held by institutional investors. Comparatively, 32.2% of Virpax Pharmaceuticals shares are held by institutional investors. 5.5% of Aridis Pharmaceuticals shares are held by insiders. Comparatively, 3.7% of Virpax Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Aridis Pharmaceuticals has a beta of 44.97, suggesting that its stock price is 4,397% more volatile than the broader market. Comparatively, Virpax Pharmaceuticals has a beta of -16.52, suggesting that its stock price is 1,752% less volatile than the broader market.

Summary

Aridis Pharmaceuticals beats Virpax Pharmaceuticals on 6 of the 8 factors compared between the two stocks.

How does Aridis Pharmaceuticals compare to Navidea Biopharmaceuticals?

Navidea Biopharmaceuticals (NYSE:NAVB) and Aridis Pharmaceuticals (NASDAQ:ARDS) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, analyst recommendations, valuation, dividends, risk, profitability and media sentiment.

Navidea Biopharmaceuticals has a beta of 1.76, indicating that its share price is 76% more volatile than the broader market. Comparatively, Aridis Pharmaceuticals has a beta of 44.97, indicating that its share price is 4,397% more volatile than the broader market.

0.0% of Navidea Biopharmaceuticals shares are owned by institutional investors. Comparatively, 9.6% of Aridis Pharmaceuticals shares are owned by institutional investors. 43.7% of Navidea Biopharmaceuticals shares are owned by company insiders. Comparatively, 5.5% of Aridis Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Company Net Margins Return on Equity Return on Assets
Navidea BiopharmaceuticalsN/A N/A N/A
Aridis Pharmaceuticals N/A N/A N/A

In the previous week, Navidea Biopharmaceuticals' average media sentiment score of 0.00 equaled Aridis Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Navidea Biopharmaceuticals Neutral
Aridis Pharmaceuticals Neutral

Navidea Biopharmaceuticals has higher revenue and earnings than Aridis Pharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Navidea Biopharmaceuticals$8.13K0.00-$15.18M-$0.21N/A
Aridis PharmaceuticalsN/AN/A-$30.37M$0.09N/A

Summary

Aridis Pharmaceuticals beats Navidea Biopharmaceuticals on 4 of the 7 factors compared between the two stocks.

Get Aridis Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for ARDS and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ARDS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ARDS vs. The Competition

Export
MetricAridis PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$5K$791.45M$7.16B$12.48B
Dividend YieldN/A4.84%2.66%6.52%
P/E Ratio0.001.6628.0224.70
Price / SalesN/A127.53540.3799.46
Price / CashN/A20.0649.2657.09
Price / BookN/A8.1710.966.46
Net Income-$30.37M-$3.71M$3.57B$337.01M

Aridis Pharmaceuticals Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ARDS
Aridis Pharmaceuticals
N/AN/AN/AN/A$5KN/A0.0030
VINC
Vincerx Pharma
N/A$0.01
flat		N/A-66.7%$66KN/AN/A60
SCPS
Scopus BioPharma
N/A$0.00
flat		N/AN/A$25KN/AN/A9
SMFL
Smart for Life
N/A$0.00
flat		N/AN/A$14K$11.11MN/A110
VRPX
Virpax Pharmaceuticals
N/A$0.01
flat		N/A-97.1%$14KN/AN/A7

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:ARDS) was last updated on 7/5/2026 by MarketBeat.com Staff.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...
Stansberry Research | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
Trump just signed it
A recent policy development is drawing attention from income-focused investors. According to one analyst, c...
Investors Alley | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
From the man who predicted 2008 crash…
Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...
Porter & Company | Sponsoredtc pixel